SBBP Strongbridge Biopharma plc

3.13
+0.09  (+3%)
Previous Close 3.04
Open 3.06
Price To Book 2.13
Market Cap 169,664,317
Shares 54,205,852
Volume 486,412
Short Ratio
Av. Daily Volume 460,916
Stock charts supplied by TradingView

NewsSee all news

  1. Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities

    ~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million

  2. Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director

    ~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of KEVEYIS® (dichlorphenamide)

  3. Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences

    DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

  4. Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    ~ KEVEYIS® (dichlorphenamide) Achieved $5.7 Million in Revenue Along with a Positive Contribution Margin in Third Quarter of 2019; Strongbridge Remains On-Track to Meet or Exceed the Top End of Full-Year KEVEYIS Revenue

  5. Strongbridge Biopharma plc Announces CEO Transition Plan and Provides Preliminary Third Quarter 2019 Financial Results and Corporate Updates

    DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 top-line data expected 2Q or 3Q 2020.
COR-003 (levoketoconazole) - LOGICS
Endogenous Cushing’s syndrome
Phase 3 data released August 8, 2018. Primary endpoint met.
COR-003 (levoketoconazole) - SONICS
Endogenous Cushing’s syndrome

Latest News

  1. Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities

    ~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent Increase over 2018 Revenue of $16.8 Million

  2. Strongbridge Biopharma plc Announces Additional Steps to Improve Operational Efficiencies and Appoints New Lead Independent Director

    ~ The Company Remains Focused on Completing the LOGICS Study and Submitting a New Drug Application (NDA) for RECORLEV™ (levoketoconazole), While Ensuring Continued Growth and Profitability of KEVEYIS® (dichlorphenamide)

  3. Strongbridge Biopharma plc to Present at Two Upcoming Investor Conferences

    DUBLIN, Ireland and TREVOSE, Pa., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

  4. Strongbridge Biopharma plc Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    ~ KEVEYIS® (dichlorphenamide) Achieved $5.7 Million in Revenue Along with a Positive Contribution Margin in Third Quarter of 2019; Strongbridge Remains On-Track to Meet or Exceed the Top End of Full-Year KEVEYIS Revenue

  5. Strongbridge Biopharma plc Announces CEO Transition Plan and Provides Preliminary Third Quarter 2019 Financial Results and Corporate Updates

    DUBLIN, Ireland and TREVOSE, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

  6. Strongbridge Biopharma plc to Host Third Quarter 2019 Financial Results Conference Call on November 7, 2019

    DUBLIN, Ireland and TREVOSE, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

  7. Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting

    DUBLIN, Ireland and TREVOSE, Pa., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

  8. Strongbridge Biopharma plc to Present at the 2019 Cantor Global Healthcare Conference

    DUBLIN, Ireland and TREVOSE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of

  9. Strongbridge Biopharma plc Announces RECORLEV™ (levoketoconazole) Phase 3 SONICS Data Published in The Lancet Diabetes & Endocrinology

    ~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities and Characteristic Signs and Symptoms of Cushing's Syndrome ~

  10. Strongbridge Biopharma plc to Present at the H.C. Wainwright 21st Annual Global Investment Conference and the Janney Montgomery Scott Healthcare Conference 2019

    DUBLIN, Ireland and TREVOSE, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of